Could a cancer drug shrink endometrial tumors?
NCT ID NCT01935934
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested the drug cabozantinib in 102 women with endometrial cancer that had returned or spread. The drug works by blocking enzymes that help tumors grow and by cutting off their blood supply. Researchers measured how many patients saw their tumors shrink or stop growing for at least 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cabozantinib (a drug that blocks enzymes needed for tumor growth and blood flow)
- What this could lead to
- If successful, this could point toward a new treatment option for women with endometrial cancer that has returned or spread.
- What could go wrong
- This is a phase 2 trial with a moderate number of participants, so results are not definitive. The drug may not work for all subtypes and could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL ADENOSQUAMOUS CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2, Canada
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
City of Hope South Pasadena
South Pasadena, California, 91030, United States
-
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
-
Decatur Memorial Hospital
Decatur, Illinois, 62526, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, L8V 5C2, Canada
-
Kingston Health Sciences Centre
Kingston, Ontario, K7L 2V7, Canada
-
London Regional Cancer Program
London, Ontario, N6A 4L6, Canada
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois, 60201, United States
-
Ottawa Hospital and Cancer Center-General Campus
Ottawa, Ontario, K1H 8L6, Canada
-
Southern Illinois University School of Medicine
Springfield, Illinois, 62702, United States
-
UPMC-Magee Womens Hospital
Pittsburgh, Pennsylvania, 15213, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- What raises endometrial cancer risk in black women? a study digs in
- Can immunotherapy plus hormones spare the womb in early endometrial cancer?
- Can a new drug tackle Hard-to-Treat gynecologic cancers?
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?
- Could gentle yoga and breathing ease Cancer's lingering toll?